Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008 by Dijkstra, Frederika et al.
154 The  Open  Virology  Journal, 2011, 5, 154-162   
 
  1874-3579/11  2011 Bentham Open 
Open Access 
Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands 
During the Winter 2007/2008 
Frederika Dijkstra
*,1, Marcel Jonges
1,2, Ruud van Beek
2,
 Gé A. Donker
3, François G. Schellevis
3,4, 
Marion Koopmans
1,2, Marianne A.B. van der Sande
1,5, Albert D.M.E. Osterhaus
2, Charles A.B. Boucher
2, 
Guus F. Rimmelzwaan
2 and Adam Meijer
1 
1Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, 
The Netherlands 
2Department of Virology, Erasmus Medical Centre (ErasmusMC), Rotterdam, The Netherlands 
3NIVEL, Netherlands Institute for Health Services Research, Utrecht, The Netherlands 
4Department of General Practice/EMGO Institute for Health and Care Research, VU University Medical Center, 
Amsterdam, The Netherlands 
5Julius Center for Health Sciences and Primary Care, University Medical Centre, Utrecht, The Netherlands 
Abstract: Background: Antiviral susceptibility surveillance in the Netherlands was intensified after the first reports about 
the emergence of influenza A(H1N1) oseltamivir resistant viruses in Norway in January, 2008. 
Methods: Within the existing influenza surveillance an additional questionnaire study was performed to retrospectively 
assess possible risk factors and establish clinical outcome of all patients with influenza virus A(H1N1) positive 
specimens. To discriminate resistant and sensitive viruses, fifty percent inhibitory concentrations for the neuramidase 
inhibitors oseltamivir and zanamivir were determined in a neuraminidase inhibition assay. Mutations previously 
associated with resistance to neuramidase inhibitors and M2 blockers (amantadine and rimantadine) were searched for by 
nucleotide sequencing of neuraminidase and M2 genes respectively. 
Results: Among 171 patients infected with A(H1N1) viruses an overall prevalence of oseltamivir resistance of 27% (95% 
CI: 20-34%) was found. None of influenza A(H1N1) oseltamivir resistant viruses tested was resistant against amantadine 
or zanamivir. Patient characteristics, underlying conditions, influenza vaccination, symptoms, complications, and 
exposure to oseltamivir and other antivirals did not differ significantly between patients infected with resistant and 
sensitive A(H1N1) viruses. 
Conclusion: In 2007/2008 a large proportion of influenza A(H1N1) viruses resistant to oseltamivir was detected. There 
were no clinical differences between patients infected with resistant and sensitive A(H1N1) viruses. Continuous 
monitoring of the antiviral drug sensitivity profile of influenza viruses is justified, preferably using the existing sentinel 
surveillance, however, complemented with data from the more severe end of the clinical spectrum. In order to act timely 
on emergencies of public health importance we suggest setting up a surveillance system that can guarantee rapid access to 
the latter. 
Keywords: Drug resistance, Viral, Epidemiology, Influenza A virus, H1N1 subtype, Oseltamivir, Signs and symptoms, 
Surveillance, Netherlands, Virology. 
INTRODUCTION 
  Infections with influenza viruses are responsible for 
substantial morbidity and mortality each year during the 
winter months [1]. Although vaccination is the main method 
of preventing influenza associated illness and death, 
antivirals may offer a valuable addition for influenza patients 
at high risk for complications and patient groups that cannot 
be vaccinated effectively. The influenza virus neuraminidase  
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inhibitors (NAI) zanamivir and oseltamivir were introduced 
in 1999. Similar to most other European countries, antivirals 
are not widely used in the Netherlands to treat seasonal 
influenza and to prevent complications [2]. Antivirals are 
mostly used therapeutically and prophylactically during 
influenza outbreaks in nursing homes and for the treatment 
of infected immunocompromised patients in hospitals. In 
addition, they are stockpiled as part of pandemic 
preparedness plans [3]. 
  Nevertheless, monitoring of influenza virus antiviral 
susceptibility has become more important [3]. In the 
Netherlands, the National Institute for Public Health and the 
Environment (RIVM) monitored susceptibility of influenza Influenza A(H1N1) Oseltamivir Resistance in 2007/2008 in the Netherlands  The Open Virology Journal, 2011, Volume 5    155 
viruses to antiviral drugs within the network of sentinel 
general practitioners since the 2005/2006 winter season [4]. 
  In 2005/2006 and 2006/2007 in the Netherlands, viruses 
with a lower sensitivity to the NAI were found only 
sporadically (2%), whilst a high proportion of A(H3N2) 
viruses were found to be resistant to the M2 ion-channel 
inhibitors (M2I) amantadine and rimantadine [4]. Until 2007, 
NAI resistant influenza viruses were also rarely observed 
elsewhere in the world [5-8]. However, by the end of 
January 2008, the emergence of influenza A(H1N1) 
oseltamivir resistant viruses (ORV) was first reported in 
Norway [9, 10], and shortly thereafter in several other 
European countries [11]. The resistance was associated with 
a amino acid substitution at position 275 (H275Y or H274Y 
in N2 numbering) of the neuraminidase, which confers a 
high level of resistance against oseltamivir [11]. 
  Clinical trials showed that resistance against oseltamivir 
generally developed at low incidence in patients treated with 
oseltamivir (0.32% in adults and 4.1% in children) [12]. 
However, in two small Japanese studies oseltamivir-
resistance emerged in 18% (9/50) and 16% (7/43) of treated 
Japanese children with influenza virus A(H3N2) and 
A(H1N1) infection respectively [13, 14]. Nevertheless, the 
overall evidence before the 2007/2008 season suggested that 
influenza A(H1N1) viruses carrying the H275Y substitution 
were highly compromised: their replicative potential was 
reduced and transmissibility and pathogenicity was 
decreased [12, 15]. 
  Immediately after the first reports about the relative high 
prevalence of ORV in several European countries, the 
antiviral susceptibility surveillance in the Netherlands was 
intensified and besides influenza A(H1N1) viruses obtained 
from sentinel patients (patients consulting a sentinel general 
practitioner [GP]), non-sentinel patients (mainly hospitalised 
patients) were included. In addition, a follow-up 
questionnaire study was started to determine the clinical 
characteristics of and possible risk factors for infection with 
ORV in the Netherlands. Here we report our findings of 
these integrated epidemiological and virological studies 
performed during the winter season 2007/2008. 
METHODS 
Influenza Surveillance 
  In the Netherlands, the influenza surveillance is carried 
out by the NIVEL (Netherlands Institute of Health Services 
Research) and the Dutch National Influenza Centre (NIC, a 
collaboration between the RIVM and the Erasmus Medical 
Center [ErasmusMC]). Sentinel surveillance of influenza is 
performed in the Dutch Sentinel Practice Network of 
NIVEL, a nationwide network of 45 general practices [16]. 
The specimens from this sentinel surveillance are examined 
for influenza viruses by real-time reverse-transcriptase 
polymerase chain reaction (RT-PCR) [17], full details 
available on request. Influenza virus isolates derived from 
PCR positive specimens in tissue culture [4] are used for 
phenotypic determination of antiviral susceptibility and sent 
to NIC-ErasmusMC for antigenic characterization 
determining the match with the season’s vaccine virus. In 
addition, all diagnostic laboratories in the Netherlands are 
requested, on a voluntary basis, to send in their influenza 
virus positive specimens or virus isolates to the NIC-
ErasmusMC for antigenic characterisation (non-sentinel 
surveillance). These specimens and viruses are mainly from 
hospitalized patients, because in general in the Netherlands 
diagnostics for influenza virus is done only in patients with a 
severe acute respiratory illness. Virus isolation and 
propagation at NIC ErasmusMC were done on Madin Darby 
Canine Kidney (MDCK) cells. 
Antiviral Susceptibility Monitoring 
  All influenza A(H1N1) viruses obtained from the 
influenza surveillance with date of sampling between 1st 
October 2007 and 18th May 2008 were tested for their 
antiviral susceptibility. The NAI sensitivity was determined 
using a fluorescence based NA-inhibition assay and 
expressed as the concentration of NAI needed to inhibit the 
NA enzyme activity by 50% (IC50), as described previously 
[4, 18, 19]. Presence or absence of the H275Y substitution in 
NA and amino acid substitutions associated with M2I 
resistance were determined by cycle-sequencing of the NA 
and M2 genes, respectively. For low viral load clinical 
specimens negative in tissue-culture, the presence or absence 
of H275Y was determined using pyrosequencing [11]. The 
haemagglutinin (HA1) gene was sequenced and used to study 
possible evolutionary relationships between sensitive and 
resistant viruses. DNA sequences were assembled, edited, 
translated and clustered by Neighbor Joining with Jukes & 
Cantor correction using Bionumerics V6.5 software (Applied 
Maths, Sint-Martens-Latem, Belgium). Full sequencing 
details are available upon request. 
Study on Risk Factors and Clinical Impact 
  To determine the possible impact of oseltamivir-
resistance on the severity of disease caused by A(H1N1) 
influenza viruses and to identify potential risk factors for 
infection with ORV a study was started among all (GP and 
hospital) patients diagnosed with an A(H1N1) influenza 
virus infection during the influenza season 2007/2008. We 
collected baseline variables (i.e. date of birth, sex, date of 
onset illness, date of specimen collection), information on 
symptoms and diagnosis, underlying illnesses, data about the 
clinical course, vaccination status, and treatment with 
oseltamivir or other antiviral drugs. For the sentinel patients, 
baseline data were obtained from the clinical specimen form 
and for supplementary data the GPs of the patients were 
asked to complete an additional questionnaire which was 
sent by e-mail or by regular mail. For the non-sentinel 
patients, only date of birth, sex, date of specimen collection, 
and name and location of the virologist who had sent in the 
virus was known at NIC-ErasmusMC. Therefore, patients’ 
physicians were asked to complete a questionnaire to provide 
the baseline data as well as the follow-up data. The 
questionnaires were developed in collaboration with the 
European Influenza Surveillance Scheme, European Centre 
for Disease Prevention and Control, and the World Health 
Organization. 
Data Analysis 
  Weekly incidence rates of ILI (influenza-like illness, 
defined according to the PEL criteria [16]) during the winter 
season 2007/2008 were calculated using consultation data 
from sentinel GPs and were compared to weekly incidence 156    The Open Virology Journal, 2011, Volume 5  Dijkstra et al. 
rates of ILI during the 2000/2001 season, i.e. the previous 
winter season in the Netherlands in which A(H1N1) 
influenza viruses were dominant [20, 21]. The weekly 
number of influenza viruses detected in the sentinel and non-
sentinel surveillance was calculated per type and subtype. 
  Viruses with the H275Y substitution or an IC50  100 
nM for oseltamivir were considered resistant. IC50 values of 
the remaining viruses were used in box-and-whisker plot 
analysis to identify potential outliers for NAI susceptibility 
[22]. IC50-values between 1.5 and 3 times the interquartile 
range (IQR), or more than 3 times the IQR outside the IQR 
were defined as mild or extreme outliers, respectively. After 
elimination of outliers, the remaining IC50-values were used 
to calculate the mean and standard deviation (SD) of baseline 
NAI susceptibility of Dutch influenza viruses. All IC50-
values were log-transformed prior to analysis and back-
transformed afterwards. 
  The Cochran-Armitage test for trend was used to test if 
there was a time trend in proportion of ORV. The Chi Square 
tests and Fisher exact tests were used for univariate analyses 
to compare possible risk factors and clinical characteristics 
between patients with influenza A(H1N1) ORV and 
oseltamivir sensitive viruses (OSV). In addition, odds ratio’s 
(ORs) were calculated to analyze whether potential risk 
factors were associated with ORV infection. In this analysis 
patients infected with ORV were regarded as cases and 
patients infected with OSV were regarded as controls (nested 
case-control approach). Finally, risk ratio’s (RRs) were 
calculated to determine the possible impact of ORV on the 
severity of disease. In this analysis patients infected with 
ORV were regarded as the exposed group and patients 
infected with OSV were regarded as the unexposed group 
(cohort approach). Analyses were done separately for 
sentinel and non-sentinel patients because of the major 
differences in for example age, symptoms, complications, 
and hospitalizations between these patient groups. Statistical 
analyses were performed using SAS software version 9.1 
(SAS Institute, Cary, NC, USA). 
RESULTS 
ILI Incidence and Circulating Influenza Viruses in the 
2007/2008 Season 
  During the 2007/2008 season, weekly ILI incidences 
were above the epidemic baseline threshold from the fifth till 
the tenth week of 2008, as well in weeks 12 and 13 [16, 23] 
and peaked later than during the 2000/2001 season (Fig. 1A). 
The mean weekly incidence of ILI in the 2007/2008 season 
(4.1 per 10,000 population) was somewhat higher compared 
to that for the 2000/2001 season (3.1 per 10,000 population), 
while peak incidence levels were comparable in both 
seasons. The number of influenza virus detections started to 
rise from the first week of 2008 (Fig. 1A). In the beginning 
of the epidemic most influenza viruses were of type A, while 
from week 10 onwards, most influenza viruses were of type 
B. Influenza A(H3) viruses were detected only sporadically. 
Study Population 
  The study population consisted of patients from both 
sentinel and non-sentinel surveillance who tested positive for 
A(H1N1) influenza virus (Table 1). From the non-sentinel  
 
surveillance 100 A(H1N1) virus isolates and respiratory 
secretions were received during the 2007/2008 season. In the 
sentinel surveillance a total of 846 respiratory specimens 
were obtained during the 2007/2008 seasons, of which 73 
(8.6%) were tested positive for A(H1N1) influenza virus by 
PCR. Two specimens had a too low viral load for virus 
isolation or pyrosequencing and therefore determination of 
antiviral susceptibility was not possible. Thirty-eight of the 
PCR-positive respiratory specimens yielded influenza 
A(H1N1) virus isolates, which were tested phenotypical for 
antiviral susceptibility and a subset of 28 by sequencing. The 
remaining 33 sentinel specimens were analyzed for antiviral 
susceptibility by pyrosequencing only. In the non-sentinel 
surveillance a total of 96 A(H1N1) virus isolates, which 
were all tested phenotypically and genotypically for antiviral 
susceptibility, and four A(H1N1) PCR-positive respiratory 
secretions, which were tested for antiviral susceptibility by 
H275Y detection only, were received from other laboratories 
during the 2007/2008 season. In total, the antiviral profile 
was available for viruses detected in 71 sentinel patients and 
100 non-sentinel patients, which were included in the 
clinical follow-up study. 
  These specimens were sent for analysis by 30 GPs and 16 
laboratories nationwide, respectively. Twenty-five GPs and 
physicians related to 12 laboratories responded to the 
questionnaires. Basic clinical data (i.e. data from clinical 
specimen form) were available for all 71 sentinel patients. 
Complete data (i.e. data from clinical specimen form and 
additional questionnaire) were obtained for 53/71 (74.6%) of 
sentinel patients. For the non-sentinel patients, complete data 
was obtained for 49/100 (49.0%) patients, while for 32 
(32%) only sex, date of birth, geographic location, and date 
of sample collection was available. 
  Age of patients from the sentinel surveillance (median 
26.2 years) was significantly higher than age of patients from 
the non-sentinel surveillance (median 0.9 years, p<0.001) 
(Table 2). Furthermore, prevalence of being immunocompro-
mised as well as having a chronic disease was higher in 
patients from the non-sentinel surveillance compared to 
patients from the sentinel surveillance (p<0.01) (Table 2). 
Sensitivity to Antiviral Drugs 
  Phenotypic assessment of the NAI sensitivity of all 
influenza A(H1N1) isolates (n=134) indicated that 29% of 
the viruses was resistant against oseltamivir (Table 1), but 
sensitive to zanamivir (mean IC50  ± SD: 0.87±0.22nM). 
Amino acid sequence analysis of the A(H1N1) isolates 
confirmed the presence of the H275Y substitution in the NA 
of all these ORVs. Sequence analysis of all 37 A(H1N1) 
virus PCR-positive specimens from which virus could not be 
isolated demonstrated the presence of the H275Y 
substitution in 7 (19%) of the samples. Sequence analysis of 
M2 of 46 sentinel influenza A(H1N1) viruses showed that 
neither in ORVs nor in OSVs known M2I resistance 
substitutions were detected. The combined phenotypic and 
genotypic data showed that 27% of Dutch influenza 
A(H1N1) viruses were resistant against oseltamivir (Table 
1), but sensitive to zanamivir and M2I. In addition to the 39 
oseltamivir resistant A(H1N1) viruses detected by   
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Fig. (1). A) Weekly incidence of ILI consultations in Dutch Sentinel Practices during the winter seasons 2007/2008 and 2000/2001, and 
number of detection of influenza viruses in Dutch Sentinel Practices and non-sentinel surveillance together during winter season 2007/2008. 
B). Weekly number of detections of influenza A(H1N1) oseltamivir resistant and sensitive viruses from the sentinel and non-sentinel 
surveillance during the winter season 2007/2008. 
 
Table 1.  Results of Phenotypic (Amount of NAI Resistance Measured by IC50-Value for Oseltamivir) and Genotypic Analysis 
(Presence of Substitution H275Y in the NA) to Determine Oseltamivir Resistance of Influenza A(H1N1) Viruses 
 
Source of Influenza 
Viruses A(H1N1) 
Phenotypic Analysis 
Only 
Genotypic 
Analysis Only 
Phenotypic and 
Genotypic Analysis 
Phenotypic Oseltamivir 
Susceptibility  Combined Analysis 
  Increased IC50-
values
a, n/N (%)  
H275Y in NA, 
n/N (%) 
Increased IC50-values
a and 
H275Y in NA, n/N (%) 
Mean (and range) of IC50-value 
of viruses with increased IC50-
values, 
a nM  
Oseltamivir 
resistance
b, n/N (%) 
Sentinel   4/10 (40%)  5/33 (15%)  5/28 (18%)
c   362,5 (282 – 538)
d 14/71  (19.7%) 
Non-sentinel     2/4 (50%)  30/96 (31%)   470 (290 - 828)  32/100 (32%) 
Overall (sentinel and 
non-sentinel) 
4/10 (40%)   7/37 (19%)  35/124 (18%)  448 (282 – 828)  46/171 (27%) 
a. >100-fold compared to NAI sensitive A(H1N1) viruses (mean±SD IC50-value: 1.21±0.41nM). 
b. With >100-fold increased IC50-values OR H275Y in NA. 
c. 1 mixed population included (wild type, H275Y). 
d. 1 mixed population excluded. 
NAI = neuraminidase inhibitors; NA = neuraminidase; IC50 = 50% inhibitory concentration. 
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phenotypic analysis, box-and-whisker plots identified three 
outliers with reduced zanamivir susceptibility, having IC50-
values of 3.1nM, 3.4nM and 5.3nM. The baseline zanamivir 
IC50-value was consequently adapted from 1.05±0.61nM to 
0.98±0.40nM (mean±SD). 
  The number of ORVs and OSVs detected by week is 
shown in Fig. (1B). Oseltamivir-resistant influenza A(H1N1) 
viruses were collected between week 52 of 2007 until week 
12 of 2008. No significant increase in the proportion ORV 
over time was detected (p>0.05) and no significant 
Table  2.  Patient Characteristics and Possible Risk Factors (Influenza Vaccination Status, Exposure to Oseltamivir, and 
Underlying Illnesses) by Source of the Sample and by Oseltamivir Susceptibility of the A(H1N1) Virus 
 
Sentinel Non-Sentinel 
Baseline Characteristics 
Resistant n=14  Sensitive n=57  OR (95%BI)  Resistant n=32  Sensitive n=68  OR (95%BI) 
Age in years:             
 median, range  25 (0.7 - 43)  27 (0.8 – 65)  NA  0.8 (0.3 -22)  0.9 (0.1 – 67)  NA 
Sex (%man)  6/14 (43%)  28/57 (49%)  0.8 (0.2 - 2.5)  15/32 (47%)  29/58 (50%)  0.9 (0.4 – 2.1) 
Province (NH+ZH)  11/14 (78.6%)  17/57 (29.8%)   8.6 (2.1 – 34.9)   No province associated distribution 
Vaccinated  1/14 (7.1%)  2/57 (3.5%)  2.1 (0.2 – 25.2)  1/18 (5.6%)  2/27 (7.4%)  0.7 (0.1 – 8.8) 
Travelled abroad  0/14  2/54 (3.7%)  NA  0/17  0/21  NA 
Oseltamivir use patient
a  0/14  1/57 (1.7%)  NA   0/20  0/28  NA 
Oseltamivir use contact
a 0/13  0/57  NA  0/20  1/23  (4.4%)  NA 
Respiratory allergy
b  0/14   2/57 (3.5%)   NA  1/17 (5.9%)  1/28 (3.6%)  1.7 (0.1 – 28.9) 
Immunocompromised  0/14  0/57  NA  4/20 (20.0%)  2/28 (7.1%)  3.3 (0.5 -19.8) 
Chronic disease  1/14 (7.1%)  4/57 (7.0%)  1.0 (0.1 – 9.9)  5/20 (25.0%)   7/28 (25.0%)  1.0 (0.3 – 3.8) 
a. within 14 days after first day of illness. 
b. respiratory allergy is the clinical presentation, in particular rhinitis, asthma and COPD, resulting from an allergic reaction of the respiratory tract following inhalation of a 
(bio)chemical allergen. 
OR= odds ratio; NA = not available; NH+ZH = Noord- and Zuid-Holland;  
'p>0.05 for all differences in course and severity between patients with a resistant virus and patients with a sensitive virus and age in 2 categories (17 years and younger and 18 
years en older). 
 
Fig. (2). Neighbor Joining phylogenetic tree inferred with Jukes & Cantor correction of Dutch influenza A(H1N1) virus neuraminidase (nt 
171-901) (left figure) and haemagglutinin (nt 184-901) (right figure) sequences. The trees were rooted on the influenza A(H1N1) vaccine 
strain A/Solomon Islands/3/2006. The trees show evidence for more amino acid variation in the receptor binding site in the haemagglutinin 
of oseltamivir resistant strains (in bold font) compared to oseltamivir sensitive strains (plain font). Substitution coding: capitals for amino 
acids and lower case for nucleotide substitutions not leading to an amino acid change. Substitutions indicated on the left side of the trees are 
valid for all sequences after the indicated node. 
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difference was observed in prevalence of ORV between 
patients from the sentinel and the non-sentinel surveillance 
(p>0.05). 
Phylogenetic Analysis 
  Based on NA sequences, oseltamivir resistance of the 
A(H1N1) influenza viruses was solely the result of amino 
acid substitution H275Y, however, accompanied by amino 
acid substitution D354G. Within the ORV strains, two NA 
types could be identified, with and without silent nucleotide 
substitution t243g (Fig. 2). Based on HA1 sequences, ORV 
strains contained silent nucleotide substitution t162c, but 
also showed more amino acid variation near the receptor-
binding site than OSV strains. In this region amino acid 
substitutions N183D, D186N/V and A189T were observed. 
The oseltamivir resistant NA carrying the silent t243g 
nucleotide substitution, was associated with amino acid 
substitution A189T in HA1. 
Risk Factors and Clinical Impact 
Clinical Diagnosis 
  Most influenza A(H1N1) infected patients from the 
sentinel surveillance were diagnosed with ILI (78.6% and 
77.2% of the patients with ORV and OSV respectively), 
while patients from the non-sentinel surveillance were 
mostly diagnosed with Acute Respiratory Infections other 
than ILI (ARI) (65.0% and 82.1% of the patients with ORV 
and OSV respectively). Specific diagnoses for patients with 
other ARI from the sentinel surveillance were common cold, 
sinusitis, otitis media, pharyngitis, tonsillitis, and bronchitis, 
whereas for patients from non-sentinel surveillance these 
were mostly common cold, bronchiolitis, pneumonia, and 
other diagnoses. 
Clinical Symptoms 
  Symptoms of patients infected with ORV and OSV are 
shown in Fig. (3). An acute start, fever, and coughing were 
the most frequently (>80%) reported symptoms in sentinel 
patients. In non-sentinel patients these symptoms were less 
frequently reported. No significant differences between 
patients with ORV and OSV were observed for any of the 
symptoms. In addition, no significant difference was 
observed in the number of reported symptoms per patient 
between these groups. 
Possible Risk Factors 
  Prevalence of ORV was significantly higher for sentinel 
patients who were sampled in a sentinel practice in the 
provinces North- and South-Holland (the west of the 
country) compared to other provinces (OR=8.6, 95% CI 2.1 
– 34.9) (Table 2). None of the patients with ORV had used 
oseltamivir themselves in the two weeks before sampling 
and only one patient was exposed to a household contact 
who had used oseltamivir. In addition, none of the other 
possible risk factors were significantly associated with ORV 
infection (Table 2). 
 
Fig. (3). Percentage of patients for whom the above mentioned symptoms were reported by oseltamivir susceptibility of the influenza 
A(H1N1) virus and by source of the influenza virus, sentinel or non-sentinel. 
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Influenza A(H1N1) oseltamivir resistant virus in sentinel patients. N=14
Influenza A(H1N1) oseltamivir sensitive virus in sentinel patients. N=57
Influenza A(H1N1) oseltamivir resistant virus in non-sentinel patients. N=21
Influenza A(H1N1) oseltamivir sensitive virus in non-sentinel patients. N=28
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Clinical Course 
  For sentinel as well as for non-sentinel patients the 
course and severity of illness of infection was independent of 
oseltamivir sensitivity profile of the influenza A(H1N1) 
viruses (Table 3). 
DISCUSSION 
  In Europe and worldwide, influenza A(H1N1) 
oseltamivir resistant viruses started to spread during the 
2007/2008 winter season. Prevalence of resistant viruses 
varied considerably from country to country [6, 24-28]. In 
the Netherlands we found an overall prevalence of 
oseltamivir resistance of 26.9% (95%CI 20.3 – 33.6%) 
among 171 A(H1N1) viruses analysed during the winter 
season 2007/2008. This prevalence was somewhat higher 
than the average prevalence of ORV in Europe (20.1%, 
95%CI 15.2-24.6%) [27]. All ORVs in the Netherlands were 
still susceptible to amantadine and zanamivir. 
  In our study none of the patients with an ORV infection 
had used oseltamivir themselves in the two weeks before 
sampling and only one was exposed to a household contact 
who had used oseltamivir. Therefore, a causal relation 
between use of oseltamivir and ORV in the Netherlands was 
quite unlikely. This finding is consistent with the low 
number of oseltamivir prescriptions in the Netherlands (15-
266 prescriptions per month in public pharmacies in the 
period July 2006 till June 2008 for the entire Dutch 
population of 16 million, source: Stichting Farmaceutische 
Kengetallen). Similar studies from other countries also did 
not demonstrate a relation between use of oseltamivir and 
ORV [10, 24, 28]. These findings are consistent with the 
lack of an association between ORV and the use of 
oseltamivir in 12 European countries [2]. 
  Between sentinel and non-sentinel patients there were 
major differences in age, hospitalization, and chronic 
conditions, which are related to the settings from which 
specimens were derived. The non-sentinel specimens 
represent a selection of influenza viruses from the more 
severe, hospitalized, patients, while sentinel specimens were 
from patients consulting a GP and likely present with less 
severe disease. Because of these differences between sentinel 
and non-sentinel patients, analyses were done separately for 
these two groups. 
  Both for sentinel and for non-sentinel patients age, 
gender, travelling abroad, underlying condition (measured as 
the presence or absence of a chronic disease, 
immunosuppression, and respiratory allergy), and 
vaccination status were similar for patients infected with 
ORV and OSV. The prevalence of ORV was significantly 
higher for sentinel patients that were sampled in sentinel 
practices in the provinces North- and South-Holland (the 
most densely populated provinces of the Netherlands) 
compared to other provinces. No clear explanation for this 
observation could be found. 
  The clinical course was similar for patients with OSR and 
OSV when assessing initial clinical symptoms, 
complications, hospitalization, and time to recovery. This 
finding is consistent with studies from Norway and the U.S. 
[10, 24]. However, mainly milder complications could have 
been missed, because it is conceivable that the physicians 
were not always aware of the exact clinical course of the 
patients in the period of 4 weeks after the sampling. At the 
moment of the questionnaire, GPs of the sentinel 
surveillance did not know the oseltamivir resistance status of 
the patient, so for the sentinel patients this could not have 
affected the answers to the questions about clinical course. 
Physicians and virologists of the included patients from the 
non-sentinel surveillance could in theory be aware of the 
oseltamivir resistance status of their patients if testing 
oseltamivir resistance was also performed in a peripheral 
laboratory on request of the peripheral virologist and/or 
physicians. However, on inquiry only one of the physicians/ 
virologists reported that testing of oseltamivir resistance was 
performed in a peripheral laboratory for 3 of their patients in 
this study. 
  The relatively mild influenza season in the Netherlands, 
which was comparable with the 2000/2001 influenza season, 
suggested that on the population level, morbidity was not 
increased because of the emergence of ORV. However, for 
individuals at high risk of complications following influenza 
virus infection (for example immunocompromised patients), 
an influenza virus infection can be life-threatening in case 
the infection is not treated (or prevented) effectively. For 
these patients infection with an ORV may have had a high 
clinical impact and even could be fatal [29, 30], although a 
fatal outcome could also occur following an infection with 
an OSV. It should be noted that our study included only one 
Table 3.  Course and Severity of Illness by Source Patient and Oseltamivir Susceptibility A(H1N1) Virus 
 
Sentinel Non-sentinel 
Category 
Resistant (n=14)  Sensitive (n=57)  RR (95%CI)  Resistant (n=32)  Sensitive (n=68)  RR (95%CI) 
Complications <4w  2/13 (15.4%)  3/39 (7.7%)  2.0 (0.4 -10.7)  6/19 (31.6%)  8/27 (29.6%)  1.1 (0.4 – 2.6) 
Death <4w  0/13  0/40  -  1/21 (4.8%)  0/26  NA 
Hospitalization <4w  1/13 (7.7%)  0/40  NA  14/21 (66.7%)  15/26 (57.7%)  1.2 (0.7 – 1.8) 
Recovered <4w  13/13 (100%)  39/40 (97.5%)  NA  15/19 (79.0%)  25/27 (92.6%)  0.9 (0.7- 1.1) 
Median number of days to recovery  
(IQR) 
15 (10 – 16)  7 (7 – 14)  NA  12 (7 - >28)  6.5 (4 -14)  NA 
RR= relative risk. 
<4w = within 4 weeks after first day of illness. 
NA = not available. 
p>0.05 for all differences in course and severity between patients with a resistant virus and patients with a sensitive virus. Influenza A(H1N1) Oseltamivir Resistance in 2007/2008 in the Netherlands  The Open Virology Journal, 2011, Volume 5    161 
of the 3 deceased Dutch patients who were infected with an 
ORV and previously described in literature [29, 30]. 
  Close monitoring of HA and NA gene segments 
composition of resistant and sensitive viruses in conjunction 
with patient information offered the opportunity to analyse the 
impact of micro-evolution on clinical and epidemiological 
presentation. During the 2007-2008 influenza season, clustering 
of A(H1N1) virus strains was observed due to micro-evolution 
in HA and NA gene segments. One oseltamivir resistant 
A(H1N1) cluster, carrying the amino acid substitution A189T 
(193 in H3 numbering) near the receptor binding site of HA, 
was associated with the NA cluster carrying silent nucleotide 
substitution t243g. Influenza viruses within the A189T HA 
cluster were obtained from both sentinel and non-sentinel 
surveillance throughout the influenza season. The first was 
obtained from a hospitalised patient in December 2007. In 
recent globally detected influenza A(H3N2) viruses, variation at 
the same location (S193F) was associated with the fixation of 
adamantane resistance caused by S31N in M2 [31]. As the 
A189T HA cluster proved dominant in the oseltamivir resistant 
A(H1N1) viruses in South Africa in 2008 [26], we hypothesize 
that A189T in HA possibly re-established the HA and NA 
balance in recent ORV variants, as suggested by Collins et al., 
[32]. Although Norway was the first country to report 
unprecedented high prevalence of influenza A(H1N1) ORV at 
the onset of the 2007-2008 epidemic, the A189T HA cluster 
was not detected in Norwegian sequences [10]. This would 
exclude Norway as contributor for global spread and fixation of 
oseltamivir resistance. Moreover, as resistant viruses belonging 
to the A189T HA cluster simultaneously co-emerged in Canada, 
the United States and Europe late 2007, it suggests that 
acquisition of oseltamivir resistance was the result of 
independent introductions and was not drug induced [2, 27]. 
Recent evidence showed that pre-existing amino acid 
substitutions in the neuraminidase itself (R222Q and V234M) 
were necessary substitutions needed for sustained 
transmissibility of the resistant H275Y variant [33]. These 
substitutions increase the number of NA proteins on the virus 
whilst the H275Y substitution reduces the number of surface 
expressed NA proteins, thereby balancing NA and HA activity 
again. Therefore, possibly in addition to the A189T substitution 
in HA the R222Q and V234M substitutions in NA created the 
prerequisites for the emergence of the H275Y variant. All the 
Dutch viruses of the 2007/2008 season possessed the R222Q 
and V234M substitutions in accordance with the data presented 
by Bloom et al., [33]. However, the D354G substitution in the 
NA distinguished ORV from OSV, as has been observed for all 
European ORV [27]. The clinical and epidemiological studies 
demonstrated that no significant differences were found 
between symptoms and patients infected with OSV or ORV, 
and therefore mutations accompanying H275Y were not 
associated with changes in the severity of infection. 
  Finally, from the experience during this study some lessons 
can be learned. Firstly, gathering additional data about patients 
diagnosed with influenza virus in the non-sentinel surveillance 
turned out to be extremely difficult and time consuming, 
because the non-sentinel surveillance is not organized to 
accommodate the possibility of tracing back patients or their 
physicians and thus collecting additional data. Consequently, 
the response to the questionnaire for the patients from the non-
sentinel surveillance was low with only 49% for a complete 
dataset. Secondly, data from regular surveillance are not by 
definition suitable for specific analytical studies, because the 
objectives for data collection for surveillance might be different 
than for a specific analytical study. Additional study protocols 
will be advisable for future studies in which virological 
characteristics of new potentially more pathogenic influenza 
strains are investigated in relation to clinical and 
epidemiological characteristics. In the Netherlands pre-
pandemic and pandemic study plans have been developed for 
such studies, that already have been used during the epidemic 
with influenza A(H1N1) 2009 [34]. The recent emergence of 
oseltamivir resistant influenza viruses in 2007-2008 as well as 
the recent pandemic of influenza A(H1N1) 2009 has shown that 
is necessary to be able to answer questions about the clinical 
impact of new potentially more pathogenic influenza strains or 
other respiratory viruses timely. Especially linked clinical and 
virological data from patients with severe acute respiratory 
infectious diseases are needed. However, specimens from 
hospitalized patients (i.e. non sentinel specimens) are sent in to 
NIC-ErasmusMC for characterization typically with minimal 
patient, clinical, and course of disease information and with a 
delay of several weeks. It has been extremely difficult to obtain 
robust clinical and course of disease information afterwards for 
these patients in this study. This phenomenon has also 
complicated a similar Europe-wide study in which only 5 
countries, including the Netherlands, were able to participate 
which could obtain follow-up data relatively easy [28]. Despite 
pre-established plans for a pandemic we had the same 
experience to obtain follow-up information on hospitalized 
patients during the A(H1N1) 2009 pandemic. To avoid these 
problems in the future, the establishment of a (national) clinical 
network of laboratories and hospitals that surveys severe acute 
respiratory infectious diseases would be preferable. In such a 
network a close interaction between surveillance and clinical 
virology is needed for rapid access to combined virological and 
clinical data. 
CONCLUSION 
  A large proportion influenza A(H1N1) oseltamivir resistant 
viruses was detected in the Netherlands in 2007-2008, whilst in 
our enhanced surveillance no significant effect on clinical 
presentation of patients was found. Hence, ORV did not confer 
more severe disease. This event provides justification for 
continuous monitoring of the antiviral drug sensitivity profile 
circulation of influenza viruses. In addition, more research is 
needed to elucidate the emergence of naturally resistant 
influenza viruses. The recent emergence of oseltamivir resistant 
influenza viruses in 2007-2008 as well as the recent pandemic 
of influenza A(H1N1) 2009 has shown that in the current 
system in the Netherlands it proved difficult to answer questions 
about the clinical impact of new potentially more pathogenic 
influenza strains or other respiratory viruses timely. Possibly, 
establishing a clinical network of laboratories and hospitals that 
surveys severe respiratory infectious diseases would fulfil this 
need. 
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